{"id":53980,"date":"2023-02-16T07:03:45","date_gmt":"2023-02-16T06:03:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/"},"modified":"2023-02-16T07:03:45","modified_gmt":"2023-02-16T06:03:45","slug":"benevolentai-notice-of-preliminary-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/","title":{"rendered":"BenevolentAI: Notice of Preliminary Results"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023.\n<\/p>\n

\nManagement will host an in-person briefing for analysts at 09:30 GMT on the day of the results at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London EC1A 4HD). The event will also be accessible via webcast and a recording of the presentation will be made available on the Company\u2019s website shortly afterwards.\n<\/p>\n

\nTo register your interest in attending either in person or virtually, please contact FTI Consulting at BenevolentAI@fticonsulting.com<\/a> or +44 (0) 20 3727 1000.\n<\/p>\n

\nAbout BenevolentAI<\/b>\n<\/p>\n

\nBenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform\u2122 powers the Company\u2019s in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEnquiries:<\/b>
BenevolentAI<\/b>
Investors:<\/b>
Fleur Wood – VP Investor Relations
\n
investors@benevolent.ai<\/a>\n<\/p>\n

\nMedia:<\/b>
Rajin Kang – VP Communications
\n
press@benevolent.ai<\/a>\n<\/p>\n

\nFTI Consulting:<\/b>
Ben Atwell, Simon Conway, Victoria Foster Mitchell
\n
+44 (0) 20 3727 1000
\n
BenevolentAI@fticonsulting.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023. Management will host an in-person briefing for analysts at 09:30 GMT on the day of the results at the offices of FTI … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53980","6":"format-standard","7":"category-industry"},"yoast_head":"\nBenevolentAI: Notice of Preliminary Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BenevolentAI: Notice of Preliminary Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023. Management will host an in-person briefing for analysts at 09:30 GMT on the day of the results at the offices of FTI ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-16T06:03:45+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BenevolentAI: Notice of Preliminary Results\",\"datePublished\":\"2023-02-16T06:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/\"},\"wordCount\":225,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/\",\"name\":\"BenevolentAI: Notice of Preliminary Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-16T06:03:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-notice-of-preliminary-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BenevolentAI: Notice of Preliminary Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BenevolentAI: Notice of Preliminary Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/","og_locale":"en_US","og_type":"article","og_title":"BenevolentAI: Notice of Preliminary Results - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023. Management will host an in-person briefing for analysts at 09:30 GMT on the day of the results at the offices of FTI ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-16T06:03:45+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BenevolentAI: Notice of Preliminary Results","datePublished":"2023-02-16T06:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/"},"wordCount":225,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/","url":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/","name":"BenevolentAI: Notice of Preliminary Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-16T06:03:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-notice-of-preliminary-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BenevolentAI: Notice of Preliminary Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53980"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53980\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}